TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06789302: A Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of DT2-SCT in Subjects With Type 2 Diabetes Mellitus

Sponsor: Global Institute of Stem Cell Therapy and Research · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 120 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06789302 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06789302 Rescue Dossier →